Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Shahram Attarian¹, Peter Young², Thomas H Brannagan³, David Adams⁴, Philip Van Damme^{5

6}, Florian P Thomas^{7

8}, Carlos Casanovas^{9

10}, Jafar Kafaie⁸, Céline Tard¹¹, Maggie C Walter¹², Yann Péréon¹³, David Walk¹⁴, Amro Stino¹⁵, Marianne de Visser¹⁶, Camiel Verhamme¹⁶, Anthony Amato¹⁷, Gregory Carter¹⁸, Laurent Magy¹⁹, Jeffrey M Statland²⁰, Kevin Felice²¹

Affiliations

¹ Reference Center for Neuromuscular Disorders and ALS, CHU La Timone, Marseille, France. Shahram.ATTARIAN@ap-hm.fr.
² Department of Neurology, Medical Park Bad Feilnbach, Bad Feilnbach, Germany.
³ Columbia University Medical Center, The Neurological Institute, New York, USA.
⁴ French Reference Center for Rare Peripheral Neuropathies, Service de Neurologie Adulte, APHP, CHU Bicêtre, Le Kremlin Bicêtre, France.
⁵ Department of Neurology, University Hospitals Leuven, KU, Leuven, Belgium.
⁶ Center for Brain & Disease Research, VIB, Leuven, Belgium.
⁷ Department of Neurology, Hackensack University Medical Center, Hackensack, USA.
⁸ Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA.
⁹ Neuromuscular Unit, Neurology Department, Bellvitge University Hospital, Barcelona, Spain.
¹⁰ Neurometabolic Diseases Group, Bellvitge Research Institute (IDIBELL) and CIBERER, Barcelona, Spain.
¹¹ U1171, Centre de référence des maladies neuromusculaires Nord Est Ile de France, Hôpital Salengro CHU de Lille, Lille, France.
¹² Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany.
¹³ Centre de Référence Maladies Neuromusculaires AOC, Filnemus, Euro-NMD, CHU Nantes, Hôtel-Dieu, Nantes, France.
¹⁴ Clinical Neuroscience Research Unit, University of Minnesota, Minneapolis, USA.
¹⁵ University of Michigan Health System, Ann Arbor, MI, USA.
¹⁶ Department of Neurology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
¹⁷ Department of Neurology, Brigham and Women's Hospital, Boston, USA.
¹⁸ St. Luke's Rehabilitation Institute, Physical Medicine and Rehabilitation, Spokane, USA.
¹⁹ CHU Dupuytren, Limoges, France.
²⁰ University of Kansas Medical Center, Kansas City, USA.
²¹ Department of Neuromuscular Medicine, Hospital for Special Care, New Britain, USA.

PMID: 38561848
PMCID: PMC10985943
DOI: 10.1186/s13023-024-03110-3

Published Erratum

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Shahram Attarian et al. Orphanet J Rare Dis. 2024.

. 2024 Apr 1;19(1):142.

doi: 10.1186/s13023-024-03110-3.

Authors

Affiliations

¹ Reference Center for Neuromuscular Disorders and ALS, CHU La Timone, Marseille, France. Shahram.ATTARIAN@ap-hm.fr.
² Department of Neurology, Medical Park Bad Feilnbach, Bad Feilnbach, Germany.
³ Columbia University Medical Center, The Neurological Institute, New York, USA.
⁴ French Reference Center for Rare Peripheral Neuropathies, Service de Neurologie Adulte, APHP, CHU Bicêtre, Le Kremlin Bicêtre, France.
⁵ Department of Neurology, University Hospitals Leuven, KU, Leuven, Belgium.
⁶ Center for Brain & Disease Research, VIB, Leuven, Belgium.
⁷ Department of Neurology, Hackensack University Medical Center, Hackensack, USA.
⁸ Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA.
⁹ Neuromuscular Unit, Neurology Department, Bellvitge University Hospital, Barcelona, Spain.
¹⁰ Neurometabolic Diseases Group, Bellvitge Research Institute (IDIBELL) and CIBERER, Barcelona, Spain.
¹¹ U1171, Centre de référence des maladies neuromusculaires Nord Est Ile de France, Hôpital Salengro CHU de Lille, Lille, France.
¹² Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany.
¹³ Centre de Référence Maladies Neuromusculaires AOC, Filnemus, Euro-NMD, CHU Nantes, Hôtel-Dieu, Nantes, France.
¹⁴ Clinical Neuroscience Research Unit, University of Minnesota, Minneapolis, USA.
¹⁵ University of Michigan Health System, Ann Arbor, MI, USA.
¹⁶ Department of Neurology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
¹⁷ Department of Neurology, Brigham and Women's Hospital, Boston, USA.
¹⁸ St. Luke's Rehabilitation Institute, Physical Medicine and Rehabilitation, Spokane, USA.
¹⁹ CHU Dupuytren, Limoges, France.
²⁰ University of Kansas Medical Center, Kansas City, USA.
²¹ Department of Neuromuscular Medicine, Hospital for Special Care, New Britain, USA.

PMID: 38561848
PMCID: PMC10985943
DOI: 10.1186/s13023-024-03110-3

No abstract available

PubMed Disclaimer

Erratum for

A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
Attarian S, Young P, Brannagan TH, Adams D, Van Damme P, Thomas FP, Casanovas C, Kafaie J, Tard C, Walter MC, Péréon Y, Walk D, Stino A, de Visser M, Verhamme C, Amato A, Carter G, Magy L, Statland JM, Felice K. Attarian S, et al. Orphanet J Rare Dis. 2021 Oct 16;16(1):433. doi: 10.1186/s13023-021-02040-8. Orphanet J Rare Dis. 2021. PMID: 34656144 Free PMC article. Clinical Trial.

References

1. Attarian, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–tooth type 1A. 2021;16:433. 10.1186/s13023-021-02040-8. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Affiliations

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Authors

Affiliations

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources